Abstract
We report a 12-year-old male patient with relapsing-remitting multiple sclerosis who showed a strong response to allopurinol with no safety concern. Researchers should further evaluate this drug option in multiple sclerosis.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
